| Quantity: | |
|---|---|
Clinical Relevance - UVB exposure in lupus-susceptible mice is similar to photosensitive CLE, including skin lesions and systemic autoimmunity.
Comprehensive endpoint conversion value technical data and verification
UVB radiation-induced CLE model in MRL/lpr mice
• Efficacy testing of local and systemic immunomodulators (corticosteroids, calcineurin inhibitors, JAK inhibitors)
• Evaluation of antimalarials (hydroxychloroquine) and biologics targeting type I interferons (anifrolumab) or B cells (rituximab)
• Target validation of photosensitivity and autoimmune pathways in CLE
• Biomarker discovery (anti-double-stranded DNA, interferon-stimulated genes)
• Pharmacology and toxicology studies to support IND
scope | Specification |
Species/Strain | MRL/lpr mice |
induction method | Repeat UVB exposure (312 nm, 100–200 mJ/cm²) on shaved back skin 3–5 times per week for 2–4 weeks |
study time | 3-6 weeks (irradiation + treatment phase) |
critical endpoint | Body weight, clinical skin score (erythema, scale, exfoliation), lymph node score, serum anti-dsDNA antibodies (ELISA), skin histopathology (HE and interface dermatitis score), optional: renal histopathology, type I interferon profile, immunofluorescence for immune complex deposition |
packet | Raw data, analysis reports, clinical scores, histological sections (skin, kidney), ELISA results, bioinformatics (optional) |
Q: Why use MRL/lpr mice as a CLE model?
A: MRL/lpr mice spontaneously develop lupus-like autoimmunity with lymphadenopathy and anti-dsDNA antibodies. UVB exposure accelerates and localizes skin manifestations, making it ideal for studying photosensitive CLE.
Q: What are the main similarities to human CLE?
A: This model exhibits photosensitive skin lesions, interface dermatitis, elevated anti-dsDNA antibodies, and immune complex deposition, very similar to human CLE (discoid, subacute, or acute forms).
Q: Can this model be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g. different UVB doses, treatment plans)?
Answer: Of course. Our scientific team tailors UVB irradiation protocols, treatment plans, and endpoint analyzes for your specific drug candidate.